Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75)

Leukemia

Volumn 27, Issue 6, 2013, Pages 1245-1253

  Mereau H ^a   De Rijck, J ^b   Cermakova K ^b   Kutz, A ^a   Juge, S ^a   Demeulemeester, J ^b   Gijsbers, R ^b   Christ, F ^b   Debyser, Z ^b   Schwaller, J ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

complex; disruption; LEDGF p75; menin; MLL

Indexed keywords

CD135 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; LENS EPITHELIUM DERIVED GROWTH FACTOR; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN P75; TRANSCRIPTION FACTOR HOXA9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL CYCLE PROGRESSION; CELL DISRUPTION; CELL IMMORTALIZATION; CLONOGENESIS; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FUSION GENE; GENE EXPRESSION; GENETIC TRANSFORMATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; STRUCTURE ANALYSIS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, EXPERIMENTAL; MICE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84878905626     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.10     Document Type: Article

References (35)

1. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000; 96: 24-33. (Pubitemid 30456446)
2. Meyer C, Schneider B, Jakob S, Strehl S, Attarbaschi A, Schnittger S et al. The mll recombinome of acute leukemias. Leukemia 2006; 20: 777-784.
3. Marschalek R. Mechanisms of leukemogenesis by mll fusion proteins. Br J Haematol 2011; 152: 141-154.
4. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 2009; 94: 984-993.
5. Smith E, Lin C, Shilatifard A. The super elongation complex (sec) and mll in development and disease. Genes Dev 2011; 25: 661-672.
6. Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I et al. Leukemia proto-oncoprotein mll forms a set1-like histone methyltransferase complex with menin to regulate hox gene expression. Mol Cell Biol 2004; 24: 5639-5649. (Pubitemid 38787950)
7. Yokoyama A, Somervaille TCP, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for mll-associated leukemogenesis. Cell 2005; 123: 207-218. (Pubitemid 41457212)
8. Yokoyama A, Cleary ML. Menin critically links mll proteins with ledgf on cancerassociated target genes. Cancer Cell 2008; 14: 36-46. (Pubitemid 351885493)
9. Liedtke M, Cleary ML. Therapeutic targeting of mll. Blood 2009; 113: 6061-6068.
10. Ge H, Si Y, Roeder RG. Isolation of cdnas encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J 1998; 17: 6723-6729. (Pubitemid 28521805)
11. Shun M-C, Raghavendra NK, Vandegraaff N, Daigle JE, Hughes S, Kellam P et al. Ledgf/p75 functions downstream from preintegration complex formation to effect gene-specific hiv-1 integration. Genes Dev 2007; 21: 1767-1778. (Pubitemid 47076476)
12. Vandekerckhove L, Christ F, Van Maele B, De Rijck J, Gijsbers R, Van den Haute C et al. Transient and stable knockdown of the integrase cofactor ledgf/p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol 2006; 80: 1886-1896. (Pubitemid 43228728)
13. Schrijvers R, De Rijck J, Demeulemeester J, Adachi N, Vets S, Ronen K et al. Ledgf/p75-independent hiv-1 replication demonstrates a role for hrp-2 and remains sensitive to inhibition by ledgins. PLoS Pathog 2012; 8: e1002558.
14. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH et al. An essential role for ledgf/p75 in hiv integration. Science 2006; 314: 461-464. (Pubitemid 44628966)
15. De Rijck J, Vandekerckhove L, Gijsbers R, Hombrouck A, Hendrix J, Vercammen J et al. Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol 2006; 80: 11498-11509. (Pubitemid 44788865)
16. Hombrouck A, De Rijck J, Hendrix J, Vandekerckhove L, Voet A, De Maeyer M et al. Virus evolution reveals an exclusive role for ledgf/p75 in chromosomal tethering of hiv. PLoS Pathog 2007; 3: e47.
17. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D et al. Rational design of small-molecule inhibitors of the ledgf/p75-integrase interaction and hiv replication. Nat Chem Biol 2010; 6: 442-448.
18. Grand FH, Koduru P, Cross NCP, Allen SL. Nup98-ledgf fusion and t(9;11) in transformed chronic myeloid leukemia. Leuk Res 2005; 29: 1469-1472. (Pubitemid 41562251)
19. Huang T, Myklebust LM, Kjarland E, Gjertsen BT, Pendino F, Bruserud O et al. Ledgf/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Mol Cancer 2007; 6: 31.
20. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo-and lymphoproliferative disease in mice by retrovirally transduced tel/jak2 fusion genes. EMBO J 1998; 17: 5321-5333. (Pubitemid 28427047)
21. Gijsbers R, Ronen K, Vets S, Malani N, De Rijck J, McNeely M et al. Ledgf hybrids efficiently retarget lentiviral integration into heterochromatin. Mol Ther 2010; 18: 552-560.
22. Liu T, Jankovic D, Brault L, Ehret S, Baty F, Stavropoulou V et al. Functional characterization of high levels of meningioma 1as collaborating oncogene in acute leukemia. Leukemia 2010; 24: 601-612.
23. Wang Q-F, Wu G, Mi S, He F, Wu J, Dong J et al. Mll fusion proteins preferentially regulate a subset of wild-type mll target genes in the leukemic genome. Blood 2011; 117: 6895-6905.
24. Drexler HG, Quentmeier H, MacLeod RAF. Malignant hematopoietic cell lines: in vitro models for the study of mll gene alterations. Leukemia 2004; 18: 227-232. (Pubitemid 38247741)
25. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ et al. Menin-mll inhibitors reverse oncogenic activity of mll fusion proteins in leukemia. Nat Chem Biol 2012; 8: 277-284.
26. Huang J, Gurung B, Wan B, Matkar S, Veniaminova NA, Wan K et al. The same pocket in menin binds both mll and jund but has opposite effects on transcription. Nature 2012; 482: 542-546.
27. Cherepanov P, Sun Z-YJ, Rahman S, Maertens G, Wagner G, Engelman A. Solution structure of the hiv-1 integrase-binding domain in ledgf/p75. Nat Struct Mol Biol 2005; 12: 526-532. (Pubitemid 43085883)
28. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV et al. Mll-rearranged leukemia is dependent on aberrant h3k79 methylation by dot1l. Cancer Cell 2011; 20: 66-78.
29. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. Rnai screen identifies brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
30. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of bet recruitment to chromatin as an effective treatment for mll-fusion leukaemia. Nature 2011; 478: 529-533.
31. Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M et al. Structure of the mll cxxc domain-dna complex and its functional role in mll-af9 leukemia. Nat Struct Mol Biol 2010; 17: 62-68.
32. Grembecka J, Belcher AM, Hartley T, Cierpicki T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J Biol Chem 2010; 285: 40690-40698.
33. Murai MJ, Chruszcz M, Reddy G, Grembecka J, Cierpicki T. Crystal structure of menin reveals binding site for mixed lineage leukemia (mll) protein. J Biol Chem 2011; 286: 31742-31748.
34. Lim DA, Huang Y-C, Swigut T, Mirick AL, Garcia-Verdugo JM, Wysocka J et al. Chromatin remodelling factor mll1 is essential for neurogenesis from postnatal neural stem cells. Nature 2009; 458: 529-533.
35. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule dot1l inhibitor. Cancer Cell 2011; 20: 53-65.